Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05800340 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 5, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.
Trial Details
NCT Number NCT05800340
Lead Sponsor Guangdong Provincial People's Hospital
Collaborators: Shanghai Junshi Bioscience Co., Ltd.
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation, MET Amplification, MET Exon 14 Skipping Mutation
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov